Clinical Trials
63 trialsPrecision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
Eilean Therapeutics
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
CML
Enliven Therapeutics
CROSSCHECK-001
Crossbow Therapeutics, Inc.
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Ascentage Pharma Group Inc.
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Incyte Corporation
TGRX-678 Pharmacokinetic Mass Balance
Shenzhen TargetRx Co., Ltd.
CML
Enliven Therapeutics
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
American Regent, Inc.
TGRX-678 Phase I Oral Pharmacokinetic Study
Shenzhen TargetRx Co., Ltd.
TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients
Shenzhen TargetRx Co., Ltd.
TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Shenzhen TargetRx Co., Ltd.
A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)
Jiangsu Hansoh Pharmaceutical Co., Ltd.
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
Kyowa Kirin Co., Ltd.
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
Novartis
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Sumitomo Pharma America, Inc.
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Karyopharm Therapeutics Inc
A Bioequivalence Study of Dasatinib Tablet
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
Xencor, Inc.
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans
Ascentage Pharma Group Inc.
Phase I Study of Milatuzumab for Graft Versus Host Disease
Gilead Sciences
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Novartis
To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib
Novartis
Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy
Novartis
USBTXA127CBT
Tarix Pharmaceuticals
Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies
Bellicum Pharmaceuticals
Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
Bio-Path Holdings, Inc.
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
Bristol-Myers Squibb
A Study for Patients With Acute Leukemia
Eli Lilly and Company
CoRNea
Novartis
Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
Takeda
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Traws Pharma, Inc.
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
AbbVie
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
Sunesis Pharmaceuticals
Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies
Prescient Therapeutics, Ltd.
Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Novartis
Effect of Food on Bioavailability of Modified Release Formulations of Imatinib
Novartis
Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib
Novartis
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
Erimos Pharmaceuticals
Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia
Bristol-Myers Squibb
Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)
Merck Sharp & Dohme LLC
MK0457 in Patients With Leukemia (0457-003)
Merck Sharp & Dohme LLC
Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia
Exelixis
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
Otsuka Pharmaceutical Co., Ltd.
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
Merck Sharp & Dohme LLC
Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Threshold Pharmaceuticals